Mostrar el registro sencillo del ítem

Osteoprotegerin and zoledronate bone effects during orthodontic tooth movement

dc.contributor.authorFernández-González F.J.
dc.contributor.authorLópez-Caballo J.L.
dc.contributor.authorCañigral A.
dc.contributor.authorMenéndez-Díaz I.
dc.contributor.authorBrizuela A.
dc.contributor.authorde Cos F.J.
dc.contributor.authorCobo T.
dc.contributor.authorVega J.A.
dc.date.accessioned2020-09-02T22:17:29Z
dc.date.available2020-09-02T22:17:29Z
dc.date.issued2016
dc.identifier10.1111/ocr.12115
dc.identifier.citation19, 1, 54-64
dc.identifier.issn16016335
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4451
dc.descriptionObjectives: To assess the effects of local delivery of recombinant fusion protein osteoprotegerin (OPG-Fc) and bisphosphonate zoledronate on bone and periodontal ligament in a rat tooth movement model. Materials and methods: Maxillary first molars of 36 male Sprague-Dawley rats were displaced mesially using a calibrated spring connected to an anterior mini-screw. Two different drugs were used: a single dose of Zoledronate (16 μg) and a twice-weekly dose of OPG-Fc (5.0 mg/kg) were injected. Tooth movement was measured on scanned plaster casts. Structural and immunohistochemical analysis of the orthodontic-induced changes in bone included receptor activator of nuclear factor K (RANK), Runx, type 1 collagen, matrix metalloproteinases (MMPs) 2 and 9, tissue inhibitors of metalloproteinases (TIMPs) 1 and 2, and vimentin. Results: Both groups showed a reduction in mesial molar displacement. Animals receiving OPG-Fc demonstrated only 52%, 31%, and 21% of the total mesial molar displacement compared to control rats at 7, 14, and 21 days, respectively (*p < 0.001). For rats receiving zoledronate tooth displacement decreased significantly with 52%, 46% and 30%, respectively (*p < 0.001). At 14 and 21 days, OPG-Fc group showed significantly less molar displacement than the zoledronate group (*p < 0.001). RANK, Runx, vimentin, MMP-9 and tissues-inhibitor metalloproteinase 1 immunoreactivity were reduced in zoledronate treated animals and even more in OPG treated animals. Conclusion: Local delivery of OPG-Fc or zoledronate inhibits bone resorption and therefore tooth movement. OPG-Fc was more effective than zoledronate in blocking the action of osteoclasts. © 2016 John Wiley & Sons A/S.
dc.language.isoen
dc.publisherBlackwell Publishing Ltd
dc.subjectBisphosphonate
dc.subjectOrthodontic anchorage
dc.subjectOsteoclasts
dc.subjectOsteoprotegerin
dc.subjectPeriodontal ligament
dc.subjectTooth movement
dc.subjectosteoprotegerin
dc.subjectanimal
dc.subjectdrug therapy
dc.subjectmale
dc.subjectorthodontic tooth movement
dc.subjectosteoclast
dc.subjectosteolysis
dc.subjectrat
dc.subjectSprague Dawley rat
dc.subjectAnimals
dc.subjectBone Resorption
dc.subjectMale
dc.subjectOsteoclasts
dc.subjectOsteoprotegerin
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectTooth Movement Techniques
dc.titleOsteoprotegerin and zoledronate bone effects during orthodontic tooth movement
dc.typeArticle


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-84954377083.pdf
Tamaño:
3.053Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem